RESUMEN
A new species of the cosmopolitan jellyfish genus Aurelia is described from the coastal waters of Mozambique using a combination of morphological, meristic and genetic information (COI and 18S). The species can be separated from congeners that have been recently described by a combination of bell shape, number of canal origins and anastomoses, and the shape of the manubrium and oral arms. Three types of nematocysts are present in the tissues of both the bell margin and oral arms, and this description of the cnidome will allow for future comparison. Pairwise genetic comparisons showed a mean COI divergence of 4.8% within the group, and a mean divergence ranging between 15% and 22% with all other species of Aurelia.
Asunto(s)
Cnidarios , Escifozoos , Animales , Mozambique , NematocistoRESUMEN
BACKGROUND AND AIMS: Stakeholders from around the world came together to address the unmet needs of underactive bladder (UAB) at the 3rd International Congress for Underactive Bladder. METHODS: The main recommendation from the regulatory working group is a need for a meeting of UAB stakeholders and regulatory agencies including the FDA to discuss guidance for regulatory trial design for devices, drugs, and/or biologics for UAB. RESULTS: The following issues to be discussed and agreed upon for UAB trials: 1) Appropriate inclusion and exclusion criteria. 2) Should residual urine volume be the primary outcome parameter and how often should it be measured? 3) Are there secondary measures that should have a place in UAB trials, such as change in the number of catheterizations, quality of life measures, etc.? 4) Use and format of bladder voiding and catheterization diary for trials. 5) Define role and technique of urodynamics in UAB trials. Are urodynamics required to monitor, and possibly exclude, individuals with high pressure voiding induced by bladder prokinetic therapies? 6) Development and use of UAB questionnaires. DISCUSSION AND CONCLUSION: The UAB regulatory working group recognizes the path forward should include engaging the FDA and other regulatory organizations that may harmonize and formalize guidance for regulatory trial designs for therapeutics for UAB.
Asunto(s)
Evaluación de la Tecnología Biomédica/métodos , Vejiga Urinaria de Baja Actividad/terapia , Betanecol/uso terapéutico , Ensayos Clínicos como Asunto , Terapia por Estimulación Eléctrica , Humanos , Agonistas Muscarínicos/uso terapéutico , Calidad de Vida , Proyectos de Investigación , Encuestas y Cuestionarios , Resultado del Tratamiento , Estados Unidos , United States Food and Drug Administration , Vejiga Urinaria de Baja Actividad/psicología , Cateterismo Urinario/estadística & datos numéricos , UrodinámicaRESUMEN
Since the collapse of the pelagic fisheries off southwest Africa in the late 1960s, jellyfish biomass has increased and the structure of the Benguelan fish community has shifted, making the bearded goby (Sufflogobius bibarbatus) the new predominant prey species. Despite increased predation pressure and a harsh environment, the gobies are thriving. Here we show that physiological adaptations and antipredator and foraging behaviors underpin the success of these fish. In particular, body-tissue isotope signatures reveal that gobies consume jellyfish and sulphidic diatomaceous mud, transferring "dead-end" resources back into the food chain.